Planning for closeout - From Day One

Contemporary Clinical Trials

Volumn 29, Issue 2, 2008, Pages 136-139

  Shepherd, Rodger ^a   Macer, Judith L ^a   Grady, Deborah ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Closeout; Contingency planning

Indexed keywords

ESTROGEN; GESTAGEN;

ARTICLE; CLINICAL TRIAL; CLOSEOUT PLANNING; COMBINATION CHEMOTHERAPY; EXPERIENCE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; PLANNING; POSTMENOPAUSE; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 39049114541     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2007.06.001     Document Type: Article

References (19)

1. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 7 (1998) 605-613
2. Montori V.M., Devereaux P.J., Adhikari N.K., et al. Randomized trials stopped early for benefit: a systematic review. JAMA 294 17 (2005) 2203-2209
3. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
4. Muth K., Yu E., Alston B., and Ellenberg J.H. The closeout process for a clinical trial terminated early for lagging enrollment and inadequate follow-up. Control Clin Trials 22 1 (2001) 49-55
5. Pressel S.L., Davis B.R., Wright J.T., et al. Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials 22 1 (2001) 29-41
6. Gilpin A.M., Holbrook J.T., Jabs D.A., and Meinert C.L. Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial. Control Clin Trials 24 1 (2003) 92-98
7. Bowen D.J., Thornquist M., Anderson K., et al. Stopping the active intervention: CARET. Control Clin Trials 24 1 (2003) 39-50
8. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 321 6 (1989) 406-412
9. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 327 4 (1992) 227-233
10. Agodoa L.Y., Appel L., Bakris G.L., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285 21 (2001) 2719-2728
11. Black H.R., Elliott W.J., Grandits G., et al. Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region. J Hypertens 23 5 (2005) 1099-1106
12. Elias P. Deaths baffle Genentech. RE: Avastin in colon cancer patients (2006), Oakland Tribune, Oakland
13. Siebels J., Cappato R., Ruppel R., Schneider M.A., and Kuck K.H. ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg. Pacing Clin Electrophysiol 16 3 Pt 2 (1993) 552-558
14. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., and Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338 10 (1998) 645-652
15. Volberding P.A., Lagakos S.W., Koch M.A., et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 322 14 (1990) 941-949
16. The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation 89 6 (1994) 2892-2907
17. Changing the protocol: a case report from the Macular Photocoagulation Study. Macular Photocoagulation Study Group. Control Clin Trials 5 3 (1984) 203-216
18. Bell R.L., Curb J.D., Friedman L.M., and Payne G.H. Termination of clinical trials: the beta-blocker heart attack trial and the hypertension detection and follow-up program experience. Control Clin Trials 6 2 (1985) 102-111
19. Palmer E.A., Hardy R.J., Davis B.R., et al. Operational aspects of terminating randomization in the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Control Clin Trials 12 2 (1991) 277-292